Evidence map›Paper›PMID 26795348›Full record

ArticleCancer research2016

Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus.

Nicola J Camp, Wei-Yu Lin, Alex Bigelow, George J Burghel, Timothy L Mosbruger, Marina A Parry, Rosalie G Waller, Sushilaben H Rigas, Pei-Yi Tai, Kristofer Berrett and 16 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 2 institutions in 2 countries.

Nicola J CampUniversity of Utah School of Medicine, Salt Lake City, Utah. nicola.camp@hci.utah.edu.
Wei-Yu LinDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Alex BigelowUniversity of Utah School of Medicine, Salt Lake City, Utah. University of Utah School of Computing, Salt Lake City, Utah.
George J BurghelDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Timothy L MosbrugerBioinformatics Shared Resource, University of Utah, Salt Lake City, Utah.
Marina A ParryDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Rosalie G WallerUniversity of Utah School of Medicine, Salt Lake City, Utah.
Sushilaben H RigasDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Pei-Yi TaiUniversity of Utah School of Medicine, Salt Lake City, Utah.
Kristofer BerrettUniversity of Utah School of Medicine, Salt Lake City, Utah.
Venkatesh RajamanickamUniversity of Utah School of Medicine, Salt Lake City, Utah.
Rachel CosbyUniversity of Utah School of Medicine, Salt Lake City, Utah.
Ian W BrockDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Brandt JonesUniversity of Utah School of Medicine, Salt Lake City, Utah.
Dan ConnleyDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Robert SargentUniversity of Utah School of Medicine, Salt Lake City, Utah.
Guoying WangUniversity of Utah School of Medicine, Salt Lake City, Utah.
Rachel E FactorUniversity of Utah School of Medicine, Salt Lake City, Utah.
Philip S BernardUniversity of Utah School of Medicine, Salt Lake City, Utah.
Lisa Cannon-AlbrightUniversity of Utah School of Medicine, Salt Lake City, Utah.
Stacey KnightUniversity of Utah School of Medicine, Salt Lake City, Utah.
Ryan AboUniversity of Utah School of Medicine, Salt Lake City, Utah.
Theresa L WernerUniversity of Utah School of Medicine, Salt Lake City, Utah.
Malcolm W R ReedDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Jason GertzUniversity of Utah School of Medicine, Salt Lake City, Utah.
Angela CoxDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
University of Utah · USUniversity of Sheffield · GB

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
UNIVERSITY OF UTAH MEDICAL INFORMATICS TRAININGT15LM007124 · NLM · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Karen Louise Eilbeck · 1997 to 2026
$22.0M
Shared Genomic Segment Analysis and Tumor Subtyping in High-Risk BrCa PedigreesR01CA163353 · NCI · UNIVERSITY OF UTAH · PI CAMP, NICOLA J. · 2012 to 2016
$2.9M
Cancer Research UK A11292NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA163353NLM NIH HHS T15 LM007124Yorkshire Cancer Research S295Yorkshire Cancer Research S299Yorkshire Cancer Research SPP060
6 · The paper itself

Abstract

The findings from genome-wide association studies hold enormous potential for novel insight into disease mechanisms. A major challenge in the field is to map these low-risk association signals to their underlying functional sequence variants (FSV). Simple sequence study designs are insufficient, as the vast numbers of statistically comparable variants and a limited knowledge of noncoding regulatory elements complicate prioritization. Furthermore, large sample sizes are typically required for adequate power to identify the initial association signals. One important question is whether similar sample sizes need to be sequenced to identify the FSVs. Here, we present a proof-of-principle example of an extreme discordant design to map FSVs within the 2q33 low-risk breast cancer locus. Our approach employed DNA sequencing of a small number of discordant haplotypes to efficiently identify candidate FSVs. Our results were consistent with those from a 2,000-fold larger, traditional imputation-based fine-mapping study. To prioritize further, we used expression-quantitative trait locus analysis of RNA sequencing from breast tissues, gene regulation annotations from the ENCODE consortium, and functional assays for differential enhancer activities. Notably, we implicate three regulatory variants at 2q33 that target CASP8 (rs3769823, rs3769821 in CASP8, and rs10197246 in ALS2CR12) as functionally relevant. We conclude that nested discordant haplotype sequencing is a promising approach to aid mapping of low-risk association loci. The ability to include more efficient sequencing designs into mapping efforts presents an opportunity for the field to capitalize on the potential of association loci and accelerate translation of association signals to their underlying FSVs. Cancer Res; 76(7); 1916-25. ©2016 AACR.

Indexed as

Breast NeoplasmsFemaleGenetic Predisposition to DiseaseGenetic VariationHaplotypesHumansPolymorphism, Single NucleotideRisk

Identifiers

PMID26795348
PMCPMC4873429
OpenAlexW2272452543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.